D-cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: A pilot randomized controlled trial

Journal of Clinical Psychiatry

Volumn 76, Issue 6, 2015, Pages e787-e793

  Levinson, Cheri A ^a   Rodebaugh, Thomas L ^a   Fewell, Laura ^b   Kass, Andrea E ^c   Riley, Elizabeth N ^a   Stark, Lynn ^b   McCallum, Kimberly ^b   Lenze, Eric J ^c  

^a WASHINGTON UNIVERSITY   (United States)

^b McCallum Place Treatment Facility ^*  (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; PLACEBO; AMINO ACID RECEPTOR STIMULATING AGENT;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; ANXIETY; ARTICLE; BEHAVIOR THERAPY; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EXPOSURE THERAPY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; YOUNG ADULT;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; BODY MASS INDEX; COMBINED MODALITY THERAPY; CYCLOSERINE; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID AGONISTS; FEMALE; HUMANS; IMPLOSIVE THERAPY; MALE; MIDDLE AGED; PILOT PROJECTS; WEIGHT GAIN; YOUNG ADULT;

EID: 84932636087     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09299     Document Type: Article

References (44)

1. Fairburn CG. Evidence-based treatment of anorexia nervosa. Int J Eat Disord. 2005;37(suppl):S26-S30, discussion S41-S42. doi:10.1002/eat.20112 PubMed
2. Beumont PJV, Russell JD, Touyz SW. Treatment of anorexia nervosa. Lancet. 1993;341(8861):1635-1640. PubMed
3. Berkman ND, Lohr KN, Bulik CM. Outcomes of eating disorders: a systematic review of the literature. Int J Eat Disord. 2007;40(4):293-309. doi:10.1002/eat.20369 PubMed
4. Finfgeld DL. Anorexia nervosa: analysis of long-term outcomes and clinical implications. Arch Psychiatr Nurs. 2002;16(4):176-186. doi:10.1053/apnu.2002.34390 PubMed
5. Herzog W, Schellberg D, Deter HC. First recovery in anorexia nervosa patients in the long-term course: a discrete-time survival analysis. J Consult Clin Psychol. 1997;65(1):169-177. doi:10.1037/0022-006X.65.1.169 PubMed
6. Herzog DB, Dorer DJ, Keel PK, et al. Recovery and relapse in anorexia and bulimia nervosa: a 7.5-year follow-up study. J Am Acad Child Adolesc Psychiatry. 1999;38(7):829-837. doi:10.1097/00004583-199907000-00012 PubMed
7. Koskina A, Campbell IC, Schmidt U. Exposure therapy in eating disorders revisited. Neurosci Biobehav Rev. 2013;37(2):193-208. doi:10.1016/j.neubiorev.2012.11.010 PubMed
8. Steinglass JE, Sysko R, Glasofer D, et al. Rationale for the application of exposure and response prevention to the treatment of anorexia nervosa. Int J Eat Disord. 2011;44(2):134-141. PubMed
9. Walsh BT. The importance of eating behavior in eating disorders. Physiol Behav. 2011;104(4):525-529. doi:10.1016/j.physbeh.2011.05.007 PubMed
10. Steinglass JE, Albano AM, Simpson HB, et al. Confronting fear using exposure and response prevention for anorexia nervosa: a randomized controlled pilot study. Int J Eat Disord. 2014;47(2):174-180. doi:10.1002/eat.22214 PubMed
11. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118-1126. doi:10.1016/j.biopsych.2008.01.012 PubMed
12. Walker DL, Ressler KJ, Lu KT, et al. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22(6):2343-2351. PubMed
13. Davis M, Ressler K, Rothbaum BO, et al. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60(4):369-375. doi:10.1016/j.biopsych.2006.03.084 PubMed
14. Hofmann SG, Smits JAJ, Rosenfield D, et al. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013;170(7):751-758. doi:10.1176/appi.ajp.2013.12070974 PubMed
15. Siegmund A, Golfels F, Finck C, et al. D-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res. 2011;45(8):1042-1047. doi:10.1016/j.jpsychires.2011.01.020 PubMed
16. Castro J, Gila A, Puig J, et al. Predictors of rehospitalization after total weight recovery in adolescents with anorexia nervosa. Int J Eat Disord. 2004;36(1):22-30. doi:10.1002/eat.20009 PubMed
17. McFarlane T, Olmsted MP, Trottier K. Timing and prediction of relapse in a transdiagnostic eating disorder sample. Int J Eat Disord. 2008;41(7):587-593. doi:10.1002/eat.20550 PubMed
18. Kaplan AS, Walsh BT, Olmsted M, et al. The slippery slope: prediction of successful weight maintenance in anorexia nervosa. Psychol Med. 2009;39(6):1037-1045. doi:10.1017/S003329170800442X PubMed
19. Levinson C, Byrne M. The Fear of Food Measure: a novel measure for use in exposure therapy for eating disorders. Int J Eat Disord. 2015;48(3):271-283. doi:10.1002/eat.22344 PubMed
20. Wolpe J. Subjective anxiety scale. In: Hersen M, Bellack AS, eds. Dictionary of Behavioral Assessment Techniques. New York, NY: Pergamon; 1998:455-457.
21. Kaplan DM, Smith T, Coons J. A validity study of the Subjective Unit of Discomfort (SUD) score. Meas Eval Couns Dev. 1995;27(4):195-199.
22. Garner DM, Olmstead MP, Polivy J. Development and validation of a multidimensional eating disorder inventory for anorexia-nervosa and bulimia. Int J Eat Disord. 1983;2(2):15-34. doi:10.1002/1098-108X(198321)2:2〈15::AID-EAT2260020203〉3.0.CO;2-6
23. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed
25. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute, 2002.
26. Steinglass J, Sysko R, Schebendach J, et al. The application of exposure therapy and D-cycloserine to the treatment of anorexia nervosa: a preliminary trial. J Psychiatr Pract. 2007;13(4):238-245. doi:10.1097/01.pra.0000281484.89075.a8 PubMed
27. Onur OA, Schlaepfer TE, Kukolja J, et al. The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans. Biol Psychiatry. 2010;67(12):1205-1211. doi:10.1016/j.biopsych.2010.01.022 PubMed
28. Santa Ana EJ, Rounsaville BJ, Frankforter TL, et al. D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. Drug Alcohol Depend. 2009;104(3):220-227. doi:10.1016/j.drugalcdep.2009.04.023 PubMed
29. Honaker J, King G, Blackwell M, et al. A program for missing data. J Stat Softw. 2011;45(7):1-47.
30. Accurso EC, Ciao AC, Fitzsimmons-Craft EE, et al. Is weight gain really a catalyst for broader recovery? the impact of weight gain on psychological symptoms in the treatment of adolescent anorexia nervosa. Behav Res Ther. 2014;56:1-6. doi:10.1016/j.brat.2014.02.006 PubMed
31. Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63(3):298-304. doi:10.1001/archpsyc.63.3.298 PubMed
32. Rothbaum BO, Price M, Jovanovic T, et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry. 2014;171(6):640-648. doi:10.1176/appi.ajp.2014.13121625 PubMed
33. Guastella AJ, Howard AL, Dadds MR, et al. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology. 2009;34(6):917-923. doi:10.1016/j.psyneuen.2009.01.005 PubMed
34. Rodebaugh TL, Levinson CA, Lenze EJ. A high-throughput clinical assay for testing drug facilitation of exposure therapy. Depress Anxiety. 2013;30(7):631-637. doi:10.1002/da.22047 PubMed
35. Bouton ME, King DA. Contextual control of the extinction of conditioned fear: tests for the associative value of the context. J Exp Psychol Anim Behav Process. 1983;9(3):248-265. doi:10.1037/0097-7403.9.3.248 PubMed
36. Craske MG, Kircanski K, Zelikowsky M, et al. Optimizing inhibitory learning during exposure therapy. Behav Res Ther. 2008;46(1):5-27. doi:10.1016/j.brat.2007.10.003 PubMed
37. Abramowitz JS. The practice of exposure therapy: relevance of cognitivebehavioral theory and extinction theory. Behav Ther. 2013;44(4):548-558. doi:10.1016/j.beth.2013.03.003 PubMed
38. Plendl W, Wotjak CT. Dissociation of within- and between-session extinction of conditioned fear. J Neurosci. 2010;30(14):4990-4998. doi:10.1523/JNEUROSCI.6038-09.2010 PubMed
39. Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. PLoS ONE. 2012;7(7):e39504. doi:10.1371/journal.pone.0039504 PubMed
40. Javitt DC. Harnessing N-methyl-D-aspartate receptors for new treatment development in psychiatry: positive lessons from negative studies. Am J Psychiatry. 2013;170(7):699-702. doi:10.1176/appi.ajp.2013.13040503 PubMed
41. Rodebaugh TL, Lenze EJ. Lessons learned from D-cycloserine: the promise and limits of drug facilitation of exposure therapy. J Clin Psychiatry. 2013;74(4):415-416. doi:10.4088/JCP.13ac08464 PubMed
42. Hofmann SG, Wu JQ, Boettcher H. D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord. 2013;3(1):11. doi:10.1186/2045-5380-3-11 PubMed
43. Smits JA, Rosenfield D, Davis ML, et al. Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial. Biol Psychiatry. 2014;75(11):840-846. doi:10.1016/j.biopsych.2013.10.008 PubMed
44. Difede J, Cukor J, Wyka K, et al. D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology. 2014;39(5):1052-1058. doi:10.1038/npp.2013.317 PubMed